Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat and Everolimus for H3K27M-Mutant Glioma
NCT03632317Phase 2Withdrawn
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Oct 2019
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in glioma and diffuse intrinsic pontine glioma (DIPG), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Median Progression Free Survival at 1 Year, Median Progression Free Survival at 2 Years and 3 more. Planned start Oct 2019; status: withdrawn.
02
Drugs
panobinostat
03
Conditions
gliomadiffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT03632317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03632317.